ay that it was targeting a valuation of up to $1.
Read the original report for the complete account of this story.
POLARIS INSIGHTS
Drug developer ADARx seeks $1.74 billion valuation in US IPO
POLARIS INSIGHTS
Read the original report for the complete account of this story.